ABSTRACT
Importance Understanding the severity of post-vaccination COVID-19 breakthrough illness among people with HIV (PWH) can inform vaccine guidelines and risk-reduction recommendations.
Objective Estimate the rate and risk of severe breakthrough illness among vaccinated PWH and people without HIV (PWoH) who experience a breakthrough infection.
Design, setting, and participants The Corona-Infectious-Virus Epidemiology Team (CIVET-II) collaboration consists of four US longitudinal cohorts from integrated health systems and academic centers. Adults (≥18 years old), in-care, fully vaccinated by June 30, 2021 with HIV, and matched PWoH (on date fully vaccinated, age group, race/ethnicity, and sex) were the source population. Those who experienced a post-vaccination SARS-CoV-2 breakthrough infection were eligible. Severe COVID-19 breakthrough illness was defined as hospitalization due to COVID-19. Discrete time proportional hazards models estimated adjusted hazard ratios (aHR) and 95% confidence intervals ([,]) of severe breakthrough illness by HIV status adjusting for demographics, COVID-19 vaccine type, and clinical factors. The proportion of patients requiring mechanical ventilation or died was compared by HIV status.
Exposure HIV infection
Outcome Severe COVID-19 breakthrough illness, defined as hospitalization within 28 days after a breakthrough SARS-CoV-2 infection with a primary or secondary COVID-19 discharge diagnosis.
Results Among 1,241 PWH and 2,408 PWoH with breakthrough infections, the cumulative incidence of severe illness in the first 28 days was low and comparable between PWoH and PWH (7.3% vs. 6.7%, respectively, risk difference=-0.67% [-2.58%, 1.23%]). The risk of severe breakthrough illness was 59% higher in PWH with CD4 counts <350 cells/mm3 compared with PWoH (aHR=1.59 [0.99, 2.46]). In multivariable analyses among PWH, being female, older, having a cancer diagnosis, and lower CD4 count increased the risk of severe breakthrough illness, while previous COVID-19 reduced the risk. Among all patients, 10% were mechanically ventilated and 8% died, with no difference by HIV status.
Conclusions and Relevance The risk of severe COVID-19 breakthrough illness within 28 days of a breakthrough infection was low among vaccinated PWH and PWoH. However, PWH with moderate and severe immune suppression had a higher risk of severe breakthrough infection. Recommendations for additional vaccine doses and risk-reduction strategies for PWH with moderate immune suppression may be warranted.
Question In 2021, among fully vaccinated people with COVID-19 breakthrough illness, was the risk of severe illness higher in people with HIV (PWH) compared to people without HIV (PWoH)?
Findings PWH with <350 cells/mm3 have a 59% increased risk of severe breakthrough illness compared to PWoH.
Meaning Vaccinations effectively reduce the risk of severe COVID-19 infection in both PWH and PWoH; however, PWH having a CD4 count <350 cells/mm3 are at higher risk of severe breakthrough infection compared to PWoH. PWH with moderate immune suppression should be considered for additional vaccine dosages and other risk-reduction measures.
INTRODUCTION
SARS-CoV-2 vaccination is an effective protective measure against coronavirus disease 2019 (COVID-19).1-3 Although uncommon, people with HIV (PWH) have a higher risk for post-vaccination (i.e. breakthrough) SARS-CoV-2 infection.4-9 Our prior study showed a 28% increased risk for breakthrough SARS-CoV-2 infection in PWH compared to people without HIV (PWoH), although breakthrough cumulative incidence was low (PWH=3.1%, PWoH=2.5%), consistent with findings among people with other immunosuppressive conditions.4,5,9 Data on breakthrough COVID-19 illness, particularly severe illness requiring hospitalization, in PWH remain sparse10,11
Studies on the severity of breakthrough COVID-19 illness by HIV status are equivocal, some finding comparable severity,12-15 while others have reported a higher risk of developing severe illness and worse outcomes, including death, for PWH compared to PWoH.16-19 Immune dysfunction is believed to increase severe COVID-19 illness risk in PWH, with lower CD4 counts and detectable HIV viral loads associated with worse outcomes.20,21 A higher risk of severe illness in PWH may be confounded by the greater comorbidity burden among PWH (compared to similar aged PWoH), including hypertension, diabetes, cardiovascular disease, and smoking.22,23 Conversely, PWH have greater immune dysfunction and a lower likelihood of hyperactive cytokine response, which may reduce the risk of severe illness in PWH.22 With global COVID-19 vaccination uptake, there is an increasing need to estimate severe COVID-19 breakthrough illness rates and risk among PWH and an appropriate control group. However, large cohorts are needed to observe sufficient breakthrough infections that progress to severe illness.
Current US Centers for Disease Control and Prevention (CDC)’s guidelines recommend risk reduction behaviors (i.e. mask wearing), an additional COVID-19 primary series vaccine dose and second booster dose for PWH having “advanced or untreated HIV infection.”24,25 PWH having partially recovered CD4 counts and moderate immune suppression are not currently recommended for an additional or second booster dose. Our objective was to determine if HIV infection was associated with increased severe COVID-19 outcomes among fully vaccinated adults with a breakthrough SARS-CoV-2 infection, and to determine the risk factors for severe COVID-19 breakthrough illness among PWH.
METHODS
Study population
The Corona-Infectious-Virus Epidemiology Team (CIVET-II) cohort is comprised of four cohorts including Kaiser Permanente Mid-Atlantic States (Maryland, District of Columbia, northern Virginia), Kaiser Permanente Northern California, University of North Carolina Chapel Hill HIV Clinic (UNC), and the Veterans Aging Cohort Study (VACS), a cohort of PWH (and similar PWoH) receiving care within the National US Veterans Affairs Healthcare System. This collaboration is an extension of the North American AIDS Cohort Collaboration on Research and Design.26 Each local institution and the Johns Hopkins Bloomberg School of Public Health institutional review board granted approval.
Adults (≥18 years old), “in-care” (Supplement Table 1), and fully vaccinated against COVID-19 between December 11, 2020 (Emergency Use Authorization of the first COVID-19 vaccine) and June 30, 2021, were eligible. Full vaccination status was defined using CDC criteria: a) 14 days after BNT162 (Pfizer) or mRNA-1273 (Moderna) mRNA vaccine second dose; or b) 14 days after Janssen Ad26.COV2.S (J&J) single dose.27 Patients with vaccines not authorized in the US were excluded.
Fully vaccinated PWH were matched to three PWoH on the date fully vaccinated (+/-14 days of the PWH vaccination date), 10-year age group, race/ethnicity, and sex at birth. Race/ethnicity was included given the disproportionate burdens of HIV by race/ethnicity. To maximize the cohort size, PWH could be matched to individuals one age group above or below their category. If three matches were unavailable, PWH were matched to one or two PWoH. The VACS (N=67,627) matches each Veteran with HIV to two Veterans without HIV per their longstanding schema, based on age, race/ethnicity, sex, and clinical site at cohort entry; VACS participants were not matched on date fully vaccinated.28
Participants were eligible for the present study if they had breakthrough COVID-19, defined as the first SARS-CoV-2 infection (detectable SARS-CoV-2 nucleic acid amplification assay [NAAT] or antigen test) or COVID-19 diagnosis (International Classification of Diseases (ICD)-10 codes [Supplement Table 2]) after the date fully vaccinated. Additional detectable SARS-CoV-2 laboratory test results and/or diagnoses occurring within +/- 90 days of breakthrough were considered persistent infection.29 If a COVID-19 diagnosis code was also identified within the 90-day window of detectable result, the first laboratory test was the breakthrough diagnosis date.
All variables were abstracted from electronic health records (EHR). Our study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines.
Outcome: Severe COVID-19 breakthrough illness
Severe COVID-19 breakthrough illness was defined as: 1) hospitalization within 28 days of breakthrough; and 2) discharge diagnosis ranked first or second was COVID-19. All discharge diagnoses were evaluated by two infectious disease physicians to exclude hospitalizations that were unlikely due to COVID-19 (trauma, surgical, non-COVID-19 infections, mental health, or substance use admissions). Only the first-ranked discharge diagnosis was available for one cohort (contributing 28% of the study population). In this cohort, if COVID-19 was not the first-ranked discharge diagnosis, and there was >1 other discharge diagnosis suggestive of COVID-19 (i.e., pneumonia due to coronavirus disease, other viral pneumonia, acute respiratory failure, or hypoxemia) the patient was classified as the outcome of severe COVID-19 breakthrough illness.
Mechanical ventilation and extracorporeal membrane oxygenation (ECMO) procedures were extracted from ICD-10 procedure and current procedural terminology (CPT) codes (Supplement Table 2) occurring between the hospital admission and discharge dates. Death occurring during or within 30 days following hospitalization or within 30 days following COVID-19 diagnosis among those not hospitalized was extracted from EHR.
Exposure: HIV infection
PWH were identified using HIV registries or HIV ICD diagnosis codes (Supplement Table 1). PWoH were classified as such if there was no evidence of HIV infection using these same sources as of December 11, 2020.
Covariates
Demographic covariates included age, race/ethnicity, and sex at birth. COVID-19 covariates included the primary series vaccine type (Pfizer, Moderna, J&J), additional vaccine dose (receipt ≥28 days after completion of primary series), and SARS-CoV-2 infection prior to date fully vaccinated (history of COVID-19). History of COVID-19 included both infections occurring prior to any vaccination or in the window between the first dose and full vaccination (partial breakthrough).
Comorbidity covariates included obesity (body mass index [BMI] ≥30 kg/m2), type 2 diabetes (DM), hypertension (HTN), end-stage renal disease (ESRD), immune suppressive conditions (organ or tissue transplantation [SOT], rheumatoid arthritis [RA], systemic lupus erythematosus [SLE]), cancer, and pregnancy. Comorbidity diagnoses were identified using ICD-10 codes, measured closest to the date fully vaccinated and after October 1, 2015; or January 1, 2020, for cancer and pregnancy only (see Supplement Table 2 for ICD-10 diagnosis codes).
Among PWH, CD4 T-cell count, and HIV-1 plasma RNA viral load suppression were collected closest to the date of full vaccination after January 1, 2020, and at antiretroviral therapy initiation (12 months prior to 1 month after). HIV viral suppression was defined as <50 copies/mL. History of AIDS diagnosis (clinical diagnosis30 or CD4 count <200 cells/mm3) prior to date fully vaccinated was included.
Statistical analysis
Study entry was the date of observed breakthrough COVID-19. Individuals were followed to date of severe breakthrough COVID-19 illness (outcome) or date of death, disenrollment from the health system (applicable to 2 of the health systems), 28 days after breakthrough COVID-19, or December 31, 2021, whichever occurred first.
Severe COVID-19 breakthrough illness monthly incidence rates (IR) per 100 person-years (PY) and 95% confidence intervals ([,]) were calculated by HIV status. Severe COVID-19 breakthrough illness cumulative incidence was estimated from the date of breakthrough COVID-19 through day 28; estimates were stratified by HIV status, and among PWH, CD4 count (<350, 350-499, and >500 cells/mm3) and viral suppression status. Using the same timescale, cumulative incidence was also estimated by HIV status for each vaccine type and for those who received an additional vaccine dose (≥28 days after primary series completion and prior to breakthrough COVID-19). Log-rank tests were calculated to test for differences in cumulative incidence and risk differences were estimated (with standard error or Wald 95% confidence intervals).
A discrete time-to-event analysis using a complimentary log-log model estimated the unadjusted and adjusted hazard ratios (aHR) with 95% confidence intervals for severe COVID-19 breakthrough illness risk by HIV status. Adjustment factors included: sex, race/ethnicity, age, additional vaccine dose following primary series, prior COVID-19, obesity, DM, HTN, ESRD, SOT, RA, SLE, cancer, and cohort. Subgroup analyses stratified by HIV status allowed for investigations into risk factors for severe COVID-19 breakthrough illness in both groups. Among PWH, prior AIDS diagnosis, HIV viral suppression and CD4 count were evaluated as risk factors for severe COVID-19. Sensitivity analyses excluded participants without first or second diagnosis code rankings.
RESULTS
Among 113,994 patients (33,029 PWH and 80,965 PWoH), there were 3,649 breakthrough COVID-19 infections (1,241 PWH and 2,408 PWoH). Of those who experienced a COVID-19 breakthrough infection, 60% were >55 years, 89% were male, 47% were non-Hispanic Black, 59% received Pfizer and 31% received Moderna for their primary series, and 15% received an additional COVID-19 vaccine dose ≥28 days after primary series completion (20% in PWH and 13% in PWoH). PWH who had CD4 count of <200 cells/mm3 (17%) and 200-349 cells/mm3 (16%) were less likely to receive an additional vaccine dose, compared to PWH with CD4 counts >350 cells/mm3 (20%) (Supplemental Table 3). Among the N=3,649 patients with breakthrough COVID, the majority (75%) were laboratory confirmed and the remainder were based on clinical diagnosis codes. Forty-nine percent of breakthroughs occurred during the Delta variant (B.1.617.2) surge from July-Oct 2021, and 41% occurred from Nov-Dec 2021 (the start of the Omicron variant [B.1.1.529] wave) (Table 1). PWH (compared with PWoH) had a lower proportion with obesity (36% vs. 54%), DM (25% vs. 34%), and HTN (51% vs. 60%) prior to vaccination. The proportion with ESRD, RA, SLE, or having received a SOT or a cancer diagnosis were similar by HIV status. Among PWH, 26% had history of AIDS prior to vaccination, 91% were virally suppressed and median CD4 count was 620 (interquartile range [IQR]: 438, 846) cells/mm3 at the time fully vaccinated.
Among those with breakthrough COVID-19, 249 (7% overall; 79 or 6% of PWH; 170 or 7% PWoH) had severe COVID-19 breakthrough illness and were hospitalized (Table 1 and Supplement Figure 1). Most (66%) hospitalizations occurred on the same day, and 81% occurred within two days following COVID-19 diagnosis. The median duration of hospitalization was 5 (IQR: 3, 8) days among PWoH and 4 (IQR: 2, 8) days among PWH. Among all hospitalized patients 10% were mechanically ventilated (Table 1). There were 33 deaths (1% overall; 12 or 1% in PWH; 21 or 1% in PWoH) that occurred during or within 30 days of hospital discharge or COVID-19 diagnosis. Supplement Table 4 describes characteristics stratified by HIV status and severe COVID-19 breakthrough illness status.
Incidence Rates (IR) and Cumulative Incidence of Severe COVID-19 Breakthrough Illness
The IR of severe COVID-19 breakthrough illness was higher among PWoH (138 [118, 160] /100 PY) versus PWH (117 [92, 145] /100 PY) (Figure 1) and relatively stable over time (Figure 1, Supplement Table 5) with slight fluctuations reflecting the bimodal distribution of the Delta and Omicron variant waves (Supplement Figure 2).
The 28-day severe COVID-19 breakthrough illness cumulative incidence was similar among PWoH (7.3% [6.3%, 8.4%]) versus PWH (6.7% [5.2% 8.1%], log rank p=0.399, risk difference=-0.67% [-2.58%, 1.23%]) (Figure 2a). PWH with lower CD4 counts (<350 cells/mm3) at full vaccination had a higher risk of severe COVID-19 breakthrough illness compared with both PWoH and PWH with CD4 counts vs. >350 cells/mm3 (Figure 2b, Supplement Figure 3). Risk did not differ by HIV viral load (Figure 2c).
Severe COVID-19 breakthrough illness risk was highest among patients with J&J for their primary vaccine series (9.3% [6.1, 12.4%]), followed by Pfizer (7.2% [6.1%, 8.3%]) and Moderna (6.2% [4.8%, 7.7%]) (Figure 3a), with no statistically significant differences by HIV status within each vaccine group. Regardless of the primary vaccine series type, having an additional dose reduced the risk of severe COVID-19 breakthrough illness in both PWH and PWoH (log-rank p=0.021, Figure 3b)
Risk factors for Severe COVID-19 Breakthrough Illness, by HIV status
There was no difference in severe COVID-19 breakthrough illness risk in PWH vs. PWoH (aHR=1.02 [0.76, 1.35]); however, there was a 59% increased risk among PWH having a CD4 count <350 cells/mm3 compared with PWoH (aHR=1.59 [0.99, 2.46], Table 2). Stratified by HIV status, PWH and PWoH had an increased risk of severe COVID-19 breakthrough illness with increasing age and decreased risk among those with an additional vaccine dose.
Among PWH, severe COVID-19 breakthrough illness risk increased with decreasing CD4 count (compared to CD4 ≥500 cells/mm3: 200-349 cells/mm3 aHR=1.65 [0.80, 3.21]; <200 cells/mm3 aHR=2.57 [1.15, 5.29]; Table 2). Female PWH had a nearly 3-fold increased severe COVID-19 breakthrough risk compared to males. Increased risk associated with non-Hispanic Black and Hispanic race/ethnicity and comorbidities ranged from 12% to 54% (p>0.05). Having a cancer diagnosis was associated with nearly 2-fold increased risk of severe COVID-19 breakthrough illness (aHR=1.97 [1.05, 3.51]).
Among PWoH, females had a reduced risk of severe COVID-19 breakthrough illness compared with males (p>0.05, Table 2). There was no observed difference in risk by race, obesity, DM, RA, SLE or having a cancer diagnosis; but there was a 4.5-fold (aHR=4.51 [2.35, 9.80]) increased risk with HTN and 2.5-fold increased risk with ESRD (aHR=2.53 [1.33, 4.56]) and SOT (aHR=2.49 [1.20, 4.96]).
Sensitivity analyses excluding patients without diagnosis code rankings did not qualitatively change findings.
Mechanical ventilation, and death in severe COVID-19 breakthrough illness
Among the 249 hospitalized patients, a greater proportion of patients with CD4 counts <350 cells/mm3 required mechanical ventilation or died during hospitalization compared to PWH with higher CD4 counts and PWoH (Supplement Figure 4). No patients received ECMO.
Patients who needed mechanical ventilation (n=24) or died (n=33) were older (>55 years), male, non-Hispanic Black, had high proportions of comorbidities, and low uptake (10-13%) of additional vaccine doses (Supplemental Table 6). Of those who had a known death during or within 30 days following COVID-19 hospitalization (n=33), the majority had comorbidities including obese BMI (68%), HTN (95%), DM (65%), ESRD (30%), SOT (20%), RA (10%), or a cancer diagnosis (25%). Among PWH who died during a severe COVID-19 breakthrough illness (n=12), 50% had a prior diagnosis of AIDS and their median CD4 count at fully vaccinated was 352 (IQR 291, 423) cells/mm3.
DISCUSSION
Prior CIVETs collaboration analyses showed a 28% increase in breakthrough COVID-19 among PWH compared with PWoH.4 Our present findings show the risk of severe illness (requiring hospitalization) after COVID-19 breakthrough was low (7% of 3,649 vaccinated PWH and PWoH) and did not differ by HIV status overall. PWH with lower CD4 counts (<350cells/mm3), however, had a 59% increase in the risk of severe COVID-19 breakthrough illness compared to PWoH, suggesting a role of immune dysfunction in the increased risk. The lack of difference in severe COVID-19 breakthrough illness risk between PWoH and PWH with higher CD4 counts may be due to engagement in medical care, different healthcare seeking behaviors and reduced comorbidities among the PWH included compared to PWoH. The increased risk of severe COVID-19 breakthrough illness for PWH with moderate (CD4 200-349 cells/mm3) immune suppression suggests they should be included with those who have advanced or untreated HIV in recommendations for additional primary series vaccination doses, second booster doses, and counseled on risk-reduction strategies.
Sex, age, comorbidities, and additional vaccine doses impact the risk of severe COVID-19 breakthrough illness.10,31-33 Among both PWoH and PWH, increasing age was the most significant risk factor for severe COVID-19 breakthrough illness in our study. Female PWoH had reduced risk, which has been previously documented;34-36 however, female PWH had increased severe risk. It is known that males and females have distinct immune system responses with females often demonstrating increased immune competence and less inflammatory immune responses, possibly contributing to their reduced risk for severe COVID-19 breakthrough illness; however, immune dysfunction with HIV may alter this effect and requires further investigation.34,37,38 Despite recommendations for additional COVID-19 vaccine doses being based in-part on CD4 count,25 we identified that the proportion of PWH who received additional doses varied little by CD4 count and was likely driven by clinical decision making and patient preference.
Among PWoH, several comorbidities have been associated with increased severe COVID-19 breakthrough illness risk.32,33,39 Our findings suggest an increased risk with HTN, ESRD, and SOT. Comorbidities were prevalent among those who experienced a severe COVID-19 breakthrough illness with 90% having a diagnosis of obesity, DM, HTN or ESRD. A lower proportion of PWH had at least one comorbidity than PWoH (82% vs 94%), yet their severe COVID-19 breakthrough rates remained the same as PWoH. Moderate to severe immune suppression from HIV itself is an important comorbidity that increases severe COVID-19 breakthrough risk; additional comorbidities and a recent cancer diagnosis increased severe COVID-19 breakthrough risk in PWH.
Limitations
Our findings may not be generalizable to all PWH, as our study population had a greater proportion of males (89%) than found in the US population of PWH, and those with higher barriers to accessing healthcare (who may be at greater risk for COVID-19) were less likely to be included in our study population. Other outcome data, including mechanical ventilation and death (particularly if death occurred out of hospital) may be under-ascertained. The discharge diagnosis ranking was not consistent as one cohort was only able to provide the primary diagnosis with the remainder unranked; however, a sensitivity analyses demonstrated no significant differences in results following exclusion of this cohort. All discharge diagnoses were reviewed by clinicians to increase specificity in our classification of COVID-19 hospitalization, but discharge coding can be influenced by many factors including reimbursement practices. Similarly, our matching schema was not consistent, but the distributions of matching factors indicate that our sample of PWH and PWoH were comparable; we included the matching factors in multivariable analyses to address residual confounding.
Conclusions
It was uncommon for COVID-19 breakthrough illness to progress to severe illness in our population of PWH and PWoH; however, PWH with moderate immune suppression (200-349 cells/mm3) had an increased severe COVID-19 breakthrough illness risk (compared to PWoH) and may benefit from being included in the CDC’s recommendation for those with “advanced and untreated HIV” to receive an additional dose in the primary COVID-19 vaccination series and second booster vaccination. Clinicians should continue to promote risk-reduction measures among PWH. The increased risk of severe COVID-19 breakthrough illness in PWH with moderate and severe immune suppression merits ongoing surveillance to inform vaccine recommendations as the pandemic persists, immunity to primary vaccine series and booster doses wane, and new variants emerge.
Data Availability
Complete data for this study cannot be publicly shared because of legal and ethical restrictions.
Funding statement
This project was made possible with supplemental funds to the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD, U01AI069918) from the National Institute of Allergy and Infectious Diseases (NIAID).
The NA-ACCORD is supported by National Institutes of Health grants U01AI069918, F31AI124794, F31DA037788, G12MD007583, K01AI093197, K01AI131895, K23EY013707, K24AI065298, K24AI118591, K24DA000432, KL2TR000421, N01CP01004, N02CP055504, N02CP91027, P30AI027757, P30AI027763, P30AI027767, P30AI036219, P30AI050409, P30AI050410, P30AI094189, P30AI110527, P30MH62246, R01AA016893, R01DA011602, R01DA012568, R01AG053100, R24AI067039, R34DA045592, U01AA013566, U01AA020790, U01AI038855, U01AI038858, U01AI068634, U01AI068636, U01AI069432, U01AI069434, U01DA036297, U01DA036935, U10EY008057, U10EY008052, U10EY008067, U01HL146192, U01HL146193, U01HL146194, U01HL146201, U01HL146202, U01HL146203, U01HL146204, U01HL146205, U01HL146208, U01HL146240, U01HL146241, U01HL146242, U01HL146245, U01HL146333, U24AA020794, U54GM133807, UL1RR024131, UL1TR000004, UL1TR000083, UL1TR002378, UL1TR002489, Z01CP010214 and Z01CP010176; contracts CDC-200-2006-18797 and CDC-200-2015-63931 from the Centers for Disease Control and Prevention, USA; contract 90047713 from the Agency for Healthcare Research and Quality, USA; contract 90051652 from the Health Resources and Services Administration, USA; the Grady Health System; grants CBR-86906, CBR-94036, HCP-97105 and TGF-96118 from the Canadian Institutes of Health Research, Canada; Ontario Ministry of Health and Long Term Care, and the Government of Alberta, Canada. Additional support was provided by the National Institute Of Allergy And Infectious Diseases (NIAID), National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), Eunice Kennedy Shriver National Institute Of Child Health & Human Development, National Human Genome Research Institute (NHGRI), National Institute for Mental Health (NIMH) and National Institute on Drug Abuse (NIDA), National Institute On Aging (NIA), National Institute Of Dental & Craniofacial Research (NIDCR), National Institute Of Neurological Disorders And Stroke, National Institute Of Nursing Research (NINR), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Deafness and Other Communication Disorders (NIDCD), and National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, the US Centers for Disease Control and Prevention or the US Government of Department of Veterans Affairs.
Competing interests
KN Althoff reports grants from the National Institutes of Health (NIH, paid to institution) and consultancy to the All of Us Research Program (NIH), TrioHealth, Kennedy Dundas, and MedIQ (paid to her).
S Napravnik, LE Browne, JK Edwards, LS Park, MA Horberg, CR Jefferson, JM Certa, J Skarbinski report grants from the NIH (paid to institution). KA Gebo reports grants from the NIH and Department of Defense (paid to the institution). R Lang reports grants from CIHR, Alberta Innovates, and the University of Calgary (paid to institution). VC Marconi has received investigator-initiated research grants (to the institution) and consultation fees (both unrelated to the current work) from Eli Lilly, Bayer, Gilead Sciences and ViiV.
BC Hogan, SB Coburn, E Humes, W Leyden, C Stewart, E Watson, KS Gordon, AC Justice, MJ Silverberg, DM Agil, KM Akgün, CF Williams report no conflicts of interest.